Vivaldi Biosciences Employee Directory
Biotechnology ResearchColorado, United States11-50 Employees
Vivaldi Biosciences is a clinical-stage biotechnology company focused on vaccines for viral respiratory diseases, delivered as nasal sprays and produced using cell-based technologies. Its DeltaFLU vaccine candidate is in Phase 2 development, and the company has pursued a Delta-19 program intended to address both influenza and COVID-19 with plans to begin clinical testing in 2021. The Delta NS1 platform uses a replication-deficient influenza vector to stimulate mucosal and systemic immune responses. The company is headquartered in Fort Collins, Colorado, and operates with a small to mid-sized team within the biotechnology research sector. In 2025, Vivaldi presented data at the World Vaccine Congress on the potential of DeltaFLU to block virus transmission, reflecting ongoing clinical evaluation.